Russell Investments Group Ltd. Makes New $1.01 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Russell Investments Group Ltd. acquired a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 39,595 shares of the company’s stock, valued at approximately $1,008,000. Russell Investments Group Ltd. owned about 0.07% of Syndax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNDX. Point72 Hong Kong Ltd bought a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at approximately $41,000. Great West Life Assurance Co. Can bought a new position in Syndax Pharmaceuticals during the 3rd quarter worth about $44,000. Royal Bank of Canada grew its holdings in shares of Syndax Pharmaceuticals by 1,144.7% in the 3rd quarter. Royal Bank of Canada now owns 3,622 shares of the company’s stock valued at $87,000 after acquiring an additional 3,331 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Syndax Pharmaceuticals by 2,488.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,659 shares of the company’s stock valued at $111,000 after acquiring an additional 4,479 shares in the last quarter. Finally, Psagot Value Holdings Ltd. Israel acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $127,000. 99.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, insider Briggs Morrison sold 52,854 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $22.53, for a total transaction of $1,190,800.62. Following the transaction, the insider now owns 17,836 shares in the company, valued at $401,845.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 158,564 shares of company stock worth $3,354,684. 4.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SNDX. Stifel Nicolaus began coverage on shares of Syndax Pharmaceuticals in a research report on Monday, January 30th. They set a “buy” rating and a $37.00 price objective for the company. HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $33.00 to $36.00 in a report on Tuesday, May 9th. Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $32.00 to $31.00 in a report on Wednesday, May 10th. JPMorgan Chase & Co. decreased their price objective on shares of Syndax Pharmaceuticals from $41.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, March 7th. Finally, The Goldman Sachs Group decreased their price target on shares of Syndax Pharmaceuticals from $39.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, March 1st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.86.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $20.33 on Friday. Syndax Pharmaceuticals, Inc. has a one year low of $14.60 and a one year high of $29.86. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -8.44 and a beta of 1.11. The firm has a fifty day moving average price of $20.98 and a two-hundred day moving average price of $23.32.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) last issued its earnings results on Monday, May 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.02. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.06 EPS for the current fiscal year.

About Syndax Pharmaceuticals

(Get Rating)

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.